The necessity of SOX9 for transcriptional plasticity has previously been seen in breast (64), lung (65), and pancreatic cancers (66); however, it has been unclear whether SOX9 is merely a marker of plasticity or if it can induce these stem properties in non-CSCs to survive cytotoxic chemotherapy. Here, SOX9 is linked to familial pancreatic carcinoma.